SENS - Senseonics Holdings Trailing Twelve Months Revenue Growth

The complex sterile delivery of devices to clinics contrasts with high patient loyalty to Senseonics Holdings (SENS) innovations. The year-over-year sales trend over the last 12 months resolves this dispute, where the value of 105.10 describes the current level of dynamics. The company's revenues are based on the sale of Eversense implantable systems for long-term glucose monitoring.
senseonics.com (SENS) - metric breakdowns and financial figures

This indicator measures actual business expansion rates over a rolling year, allowing for the identification of sales slowdowns prior to the publication of quarterly reports. By analyzing the TTM revenue growth trend, an investor assesses the effectiveness of Senseonics Holdings (SENS) expansion in the CGM market through its partnership with Ascensia and the successful implementation of long-term Eversense implants as opposed to the short-term solutions offered by competitors.